The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression.
 
Diana Bello
Travel, Accommodations, Expenses - daiichi sankyo; Lilly
 
Toon Van Gorp
Consulting or Advisory Role - AstraZeneca (Inst); BioNTech SE (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst); Tubulis GmbH (Inst); Zentalis (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
Gottfried E. Konecny
Consulting or Advisory Role - GOG Partners
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Immunogen; Merck
Research Funding - Lilly (Inst); Merck (Inst)
Expert Testimony - Foundation Medicine
Travel, Accommodations, Expenses - TORL
 
Purificación Estévez-García
No Relationships to Disclose
 
John William Moroney
Research Funding - AstraZeneca (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Merck (Inst); Mersana (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst)
 
Susana N. Banerjee
Stock and Other Ownership Interests - Perci Health
Honoraria - AstraZeneca; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Novocure; Roche; Takeda; Verastem
Consulting or Advisory Role - Astrazeneca; Epsilogen; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Myriad Genetics; Novartis; OncXerna Therapeutics; Regeneron; Seagen; Shattuck Labs; Verastem (I); Zymeworks
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Verastem
(OPTIONAL) Uncompensated Relationships - ESMO
 
Tashanna K. N. Myers
Consulting or Advisory Role - Immunogen; Immunogen
 
Claudio Zamagni
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daichi-Sankyo; EISAI; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche; Seagen
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Medivation (Inst); Morphotek (Inst); Novartis (Inst); pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seagen (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichi-Sankyo; Gilead Sciences; Novartis; Pfizer; Roche
 
Gabriella Parma
No Relationships to Disclose
 
Daniel W Sonnenburg
No Relationships to Disclose
 
Andrzej Roszak
No Relationships to Disclose
 
Roy Iqbal Lalisang
No Relationships to Disclose
 
Ronnie Shapira-Frommer
No Relationships to Disclose
 
Jaroslav Klat
No Relationships to Disclose
 
Yuemei Wang
Employment - Immunogen
 
Michael W. Method
Employment - Immunogen
Stock and Other Ownership Interests - Immunogen; Lilly
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - AADi; aadi; Alkermes (Inst); AstraZeneca; Blueprint Medicines (Inst); Caris Life Sciences; Clovis Oncology; Duality Biologics (Inst); Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); Hengrui Pharmaceutical; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Merck; Mereo BioPharma; Mersana (Inst); Myriad Genetics; Novartis; Novartis/Pfizer; Onconova Therapeutics; OncXerna Therapeutics; Regeneron; VBL Therapeutics; Verastem/Pharmacyclics; zentalis
Research Funding - Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
Other Relationship - GOG Partners (Inst)